MedTrace Logo

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

NCT00471094 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 831

Last updated 2012-02-02

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of 8 weeks of daily treatment with Ilaprazole (5, 20 and 40 mg), once daily (QD), compared to lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.

Conditions

  • Esophagitis

Interventions

DRUG

Ilaprazole

Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.

DRUG

Ilaprazole

Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.

DRUG

Ilaprazole

Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.

DRUG

Lansoprazole

Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471094 on ClinicalTrials.gov